Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mako Kato"'
Autor:
Hideto Ueki, Koichi Kitagawa, Mako Kato, Shihoko Yanase, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa, Toshiro Shirakawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell car
Externí odkaz:
https://doaj.org/article/7fe93da284264bc099e20e75187ea979
Autor:
Koichi Kitagawa, Maho Tatsumi, Mako Kato, Shota Komai, Hazuki Doi, Yoshiko Hashii, Takane Katayama, Masato Fujisawa, Toshiro Shirakawa
Publikováno v:
Molecular Therapy: Oncolytics, Vol 22, Iss , Pp 592-603 (2021)
Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) such as PD-1/PD-L1 inhibitors has been well established for various types of cancer. Monotherapy with ICIs, however, can achieve a durable response in only a subset of patients. There is
Externí odkaz:
https://doaj.org/article/3b9793af28f243d7872de85b30098864
Autor:
Hideto Ueki, Koichi Kitagawa, Mako Kato, Shihoko Yanase, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa, Toshiro Shirakawa
Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7f16792a85d68ba21d6c71d893b989a
https://doi.org/10.21203/rs.3.rs-2400009/v1
https://doi.org/10.21203/rs.3.rs-2400009/v1
Autor:
Yoshiko Hashii, Takane Katayama, Masato Fujisawa, Maho Tatsumi, Toshiro Shirakawa, Hazuki Doi, Koichi Kitagawa, Mako Kato, Shota Komai
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 22, Iss, Pp 592-603 (2021)
Molecular Therapy: Oncolytics, Vol 22, Iss, Pp 592-603 (2021)
Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) such as PD-1/PD-L1 inhibitors has been well established for various types of cancer. Monotherapy with ICIs, however, can achieve a durable response in only a subset of patients. There is
Autor:
Shota Komai, Yoshiko Hashii, Takane Katayama, Koichi Kitagawa, Toshiro Shirakawa, Mako Kato, Maho Tatsumi
Publikováno v:
Cancer Immunology Research. 7:B114-B114
Nowadays, cancer immunotherapies such as immune-checkpoint inhibitors, chimeric antigen receptor T-cells and cancer vaccines have achieved great success in cancer therapy. Nevertheless, increasing cancer antigen-specific immune responses is necessary
Publikováno v:
International Journal of Pharmaceutics. 423:428-434
Elevated interstitial fluid pressure (IFP) in a tumor is a barrier to tumor accumulation of systemic delivery of nanocarriers. In this study, we investigated whether intravenous injection of type I collagenase (collagenase-1) reduced IFP in tumors an
Autor:
Chiyonori Ino, Mako Kato, Toshio Yamashita, Y. Tohyama, Tadami Kumazawa, Makiko Ohtani, Tadashi Iwano
Publikováno v:
Practica Oto-Rhino-Laryngologica. 84:1691-1697
A new closure method was carried out on 281 ears with sizable tympanic perforations caused by trauma or chronic otitis media. This method combines trichloracetic acid cautery and a collagen sheet patch. Closure was successful in 91.1% of perforations